Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
The current Gilead Sciences(GILD) stock price is $156.09, with a market capitalization of 193.55B. The stock trades at a price-to-earnings (P/E) ratio of -59.17 and offers a dividend yield of 2.07%.
During the trading session on 2026-10-23, Gilead Sciences(GILD) shares reached a daily high of $157.65 and a low of $155.76. At a current price of $156.09, the stock is +0.2% higher than the low and still -1.0% under the high.
Trading activity shows a volume of 6.07M, compared to an average daily volume of 6.4M.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $160.51 and a low of $114.02.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $160.51 and a low of $114.02.
GILD News
Investing AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? When a drugmaker's top product loses patent protection, the dividend usually...
Gilead Sciences (GILD) announced an update on their ongoing clinical study. Gilead Sciences is running Substudy-01 under a broader platform trial to test long-...
Gilead Sciences (NasdaqGS:GILD) agreed to a global Phase 3 collaboration with BioNTech to study sacituzumab govitecan plus a checkpoint inhibitor in metastatic...
Analyst ratings
77%
of 30 ratingsMore GILD News
Gilead (GILD) Sciences announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, fr...
Texas Attorney General Ken Paxton secured $45M in a settlement with Gilead (GILD) Sciences to resolve claims that the company engaged in an illegal kickback sch...
Gilead (GILD) Sciences will present new clinical and real-world evidence across primary biliary cholangitis, PBC, and chronic hepatitis delta virus, HDV, infect...
BioNTech (BNTX) announced a clinical trial collaboration and supply agreement with Gilead Sciences (GILD) to evaluate pumitamig in combination with the TROP2-di...
Gilead Sciences (GILD Quick QuoteGILD - Free Report) closed at $153.57 in the latest trading session, marking a -1.88% move from the prior day. The stock...
Gilead Sciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterate...
Gilead Sciences Inc. (NASDAQ:GILD) on Monday announced 12-week induction data from its Phase 2 SWIFT trial evaluating emvistegrast, an investigational once-dail...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.